Schistosome vaccines.
Schistosomiasis control currently relies primarily on chemotherapy which is both expensive and temporary. There is an urgent need for an effective vaccine. Studies in animal models and man have demonstrated the existence of protective immunity. Antibody-dependent cell-mediated cytotoxicity mechanisms involving eosinophils and macrophages have been implemented in destruction of the parasites. Antigens expressed on the surface of the schistosomulum are among the targets of protective immune responses. Vaccines comprising recombinant antigens are now being tested in vivo for their capacity to evoke protective responses. Live oral vaccines based on attenuated Salmonella expressing schistosomular surface antigens are being developed.
Taylor
D W
DW
Department of Pathology, University of Cambridge, England.
D000818:Animals; D000909:Antibodies, Helminth / Q000096:biosynthesis; D000947:Antigens, Helminth / Q000008:administration & dosage / Q000276:immunology*; D002241:Carbohydrates / Q000276:immunology; D000939:Epitopes; D006801:Humans; D007111:Immunity, Cellular; D012547:Schistosoma / Q000276:immunology*; D012552:Schistosomiasis / Q000517:prevention & control*; D014611:Vaccination
D000909:Antibodies, Helminth; D000947:Antigens, Helminth; D002241:Carbohydrates; D000939:Epitopes